← Oncology Approval Tracker

FDA DECISION ·

Lumakras + Vectibix

sotorasib + panitumumab · Amgen

FDA approvalNew or expanded indicationColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with FDA-test-confirmed KRAS G12C-mutated metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The combination pairs a KRAS G12C inhibitor with EGFR blockade in previously treated colorectal cancer.

What research teams should watch

Confirm KRAS G12C status and capture exposure to all three required chemotherapy components before enrollment screening.

PRIMARY RECORDS

Sources